Molecularly targeted approaches to the treatment of malignant melanoma have in recent years seen unprecedented advances, with drugs targeting BRAF-MEK-ERK signaling now in routine clinical use, including the BRAF inhibitor vemurafenib37 and many more undergoing clinical development. The gene discussed is MAP2K7; the disease is melanoma.